Trials / Completed
CompletedNCT02575833
Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of AMG 334 on Exercise Time During a Treadmill Test in Subjects With Stable Angina
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
A phase 2a, multicenter, randomized, double-blind, placebo-controlled study in adults with stable angina to evaluate the effect of erenumab (AMG 334) compared to placebo on exercise time during an exercise treadmill test.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erenumab | A single dose of erenumab 140 mg infused over approximately 60 minutes. |
| DRUG | Placebo | A single dose of a matching volume of placebo infused over approximately 60 minutes. |
Timeline
- Start date
- 2015-11-23
- Primary completion
- 2017-01-23
- Completion
- 2017-04-13
- First posted
- 2015-10-15
- Last updated
- 2018-08-24
- Results posted
- 2018-07-05
Locations
33 sites across 10 countries: United States, Bulgaria, Czechia, Latvia, New Zealand, Poland, Romania, Slovakia, South Africa, Switzerland
Source: ClinicalTrials.gov record NCT02575833. Inclusion in this directory is not an endorsement.